Recent Advances in Liposomal-Based Anti-Inflammatory Therapy

Abstract

Liposomes can be seen as ideal carriers for anti-inflammatory drugs as their ability to (passively) target sites of inflammation and release their content to inflammatory target cells enables them to increase local efficacy with only limited systemic exposure and adverse effects. Nonetheless, few liposomal formulations seem to reach the clinic. The current review provides an overview of the more recent innovations in liposomal treatment of rheumatoid arthritis, psoriasis, vascular inflammation, and transplantation. Cutting edge developments include the liposomal delivery of gene and RNA therapeutics and the use of hybrid systems where several liposomal bilayer features, or several drugs, are combined in a single formulation. The majority of the articles reviewed here focus on preclinical animal studies where proof-of-principle of an improved efficacy–safety ratio is observed when using liposomal formulations. A few clinical studies are included as well, which brings us to a discussion about the challenges of clinical translation of liposomal nanomedicines in the field of inflammatory diseases.

MiR ‐182‐3p targets TRF2 and impairs tumor growth of triple‐negative breast cancer

“…The existence of a therapeutic window was observed in vivo showing that systemic depletion of TRF2 by LNPs‐miR‐182‐3p did not compromise proliferative and non‐proliferative mouse organs and did not induce a significant activation of DNA damage and apoptosis/senescence in highly proliferative compartments. The lack of a significant DNA damage and/or apoptosis/senescence induction may be due to multiple variables, including the different complexity of the two systems, the doses/scheduling used, and/or the intrinsic selectivity of LNPs for inflamed sites, such as tumor (Zhang et al , 2016 ; Karpuz et al , 2021 ; van Alem et al , 2021 ). However, further studies will be needed to definitely exclude possible side effects in vivo .…”

Challenges in Optimizing Nanoplatforms Used for Local and Systemic Delivery in the Oral Cavity

“…Pharmaceutics 2024, 16, 626 3 of 22 in periodontal regeneration [26], and in oral cancer [27][28][29]. The third type of reporting on the transdermal and transmucosal systems used in oral pathology are particularly focused on the various possibilities of improving absorption, whether we refer to it as a question of excipients with an amplifying effect [15,28,30] or to that of physical amplifiers (microneedles, iontophoresis, sonophoresis, and electrophoresis) [31][32][33][34]. Unlike the previously mentioned works, our work presents a more complex approach, considering a varied oral pathology as well as various types of controlled release systems that address these pathologies.…”

Nanomedicines: intervention in inflammatory pathways of cancer

“…These ligands have affinity to bind with the receptors, like αvβ 3 , αvβ 5 and α 5 β 1 integrins, overexpressed on the tumor endothelial cell surface (Slack et al 2021 ; Nestić et al 2021 ). Preclinical in vitro studies have revealed that inhibition of angiogenesis may result in suppression of existing tumors and metastasis regression (van Alem et al 2021 ). Kim et al showed that silencing of endothelial genes like VEGFR1 or delta-like protein 4 (DLL4), which are involved in angiogenesis, low molecular weight NPs efficiently delivered si-RNAs to endothelial cells, and reduced the growth and metastasis of mouse Lewis lung carcinoma (Kim et al 2021a ; Dahlman et al 2014 ).…”